New french questionnaire aims to catch Alzheimer's navigation trouble early
NCT ID NCT07616063
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a French questionnaire designed to identify spatial orientation problems in people with Alzheimer's disease. Researchers will ask 330 participants—including Alzheimer's patients, their caregivers, and healthy older adults—to fill out the questionnaire. The goal is to see if the tool is reliable and useful for spotting early signs of disorientation, which could lead to better care and support.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Questionnaire d'Orientation Spatiale (QOS) - a French version of the Wayfinding Questionnaire
- What this could lead to
- If successful, this questionnaire could become a standard tool to detect spatial disorientation early in Alzheimer's, helping doctors provide better support.
- What could go wrong
- This is an early-stage validation study, not a treatment trial. The questionnaire may not prove accurate enough for routine use, and results may not apply outside French-speaking populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 330 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with Alzheimer disease and their caregivers
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: For all subjects : * Native French speakers * Independent mobility: (minimum mobility range of 3 (i.e., neighborhood) on the LSA-F assessment of the mobility zone scale) * Person affiliated with a social security system or beneficiary of such a system Patients (Subgroup A1) and healthy control subjects (Group C): * Individuals who have received complete information about the clinical research organization and have signed their written informed consent * Patients (Subgroups A2 and A3) and Companions (Group B) Individuals who have received complete information about the clinical research and have agreed to participate Patients (group A): * Aged 55 to 85 * Diagnosis of probable Alzheimer's disease (NINCDR-ADRDA diagnostic criteria) * Score of 4 or less on the Hachinski Ischemic Scale * Score of 20 or higher on the Folstein MMSE (Mini Mental State Examination) * In the case of specific treatment for Alzheimer's disease (anticholinesterase and memantine treatments), treatment stability for \> 15 days * Able to walk independently, i.e., without assistance, whether human or technical, except for a simple cane Caregivers (group B): * Caregivers of a person with dementia included in group A, with regular contact (at least 10 hours per week, spread over a minimum of 3 times per week) * Healthy control subjects (group C): * Aged 55 to 85 * Able to walk independently, i.e., without assistance, whether human or technical, except for a single cane * Normal performance on the Folstein Mini-Mental State Examination (MMSE), according to GRECO (Cognitive Assessment Task Force) standards Exclusion Criteria: For all subjects: * Adults subject to legal protection measures (guardianship, curatorship, judicial protection) * Adults unable to give their consent * Persons deprived of their liberty by judicial or administrative decision, persons receiving psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1. * Persons capable of giving consent but unable to read French * Persons capable of giving consent but unable to write * One of the members of the patient/caregiver dyad refusing to participate in the study. Patients (subgroup A1) and healthy control subjects (group C): * Sensory or phasic deficit interfering with the task. * History of moderate or severe head trauma (with loss of consciousness). * Change in psychotropic treatment less than 48 hours before the tests * Chronic alcoholism * Severe depression (score greater than or equal to 10 on the GDS-15 Geriatric Depression Scale) * Presence of other clinically significant psychiatric or neurological conditions (except Alzheimer disease for case subjects)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer's disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHRU (Centre Hospitalier Régionale Universitaire) Nancy
Nancy, 54500, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a home device slow dementia? pilot trial tests pulsed electromagnetic therapy
- Can a video chat keep dementia care true to Patients' wishes?
- 10-Year watch: how safe is lecanemab outside clinical trials?
- Can a Melatonin-Like pill slow Alzheimer's memory loss?
- Could brain stimulation help Alzheimer's patients think more clearly?
- Could a common blood pressure pill recharge brain cells in Alzheimer's?